1. Home
  2. ORKA vs AMAL Comparison

ORKA vs AMAL Comparison

Compare ORKA & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORKA
  • AMAL
  • Stock Information
  • Founded
  • ORKA 2004
  • AMAL 1923
  • Country
  • ORKA United States
  • AMAL United States
  • Employees
  • ORKA N/A
  • AMAL N/A
  • Industry
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AMAL Commercial Banks
  • Sector
  • ORKA Health Care
  • AMAL Finance
  • Exchange
  • ORKA Nasdaq
  • AMAL Nasdaq
  • Market Cap
  • ORKA 354.2M
  • AMAL 937.6M
  • IPO Year
  • ORKA N/A
  • AMAL 2018
  • Fundamental
  • Price
  • ORKA $12.60
  • AMAL $33.35
  • Analyst Decision
  • ORKA Strong Buy
  • AMAL Buy
  • Analyst Count
  • ORKA 8
  • AMAL 3
  • Target Price
  • ORKA $39.71
  • AMAL $36.50
  • AVG Volume (30 Days)
  • ORKA 341.3K
  • AMAL 198.6K
  • Earning Date
  • ORKA 08-15-2025
  • AMAL 07-24-2025
  • Dividend Yield
  • ORKA N/A
  • AMAL 1.70%
  • EPS Growth
  • ORKA N/A
  • AMAL 9.81
  • EPS
  • ORKA N/A
  • AMAL 3.36
  • Revenue
  • ORKA N/A
  • AMAL $303,970,000.00
  • Revenue This Year
  • ORKA N/A
  • AMAL $11.72
  • Revenue Next Year
  • ORKA N/A
  • AMAL $12.48
  • P/E Ratio
  • ORKA N/A
  • AMAL $9.78
  • Revenue Growth
  • ORKA N/A
  • AMAL 7.13
  • 52 Week Low
  • ORKA $5.49
  • AMAL $25.03
  • 52 Week High
  • ORKA $52.32
  • AMAL $38.19
  • Technical
  • Relative Strength Index (RSI)
  • ORKA N/A
  • AMAL 69.84
  • Support Level
  • ORKA N/A
  • AMAL $31.13
  • Resistance Level
  • ORKA N/A
  • AMAL $31.53
  • Average True Range (ATR)
  • ORKA 0.00
  • AMAL 0.74
  • MACD
  • ORKA 0.00
  • AMAL 0.25
  • Stochastic Oscillator
  • ORKA 0.00
  • AMAL 94.07

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.

Share on Social Networks: